Search Results 61-70 of 16570 for B cell lymphomas

  1. A Study to Evaluate the Safety and Effectiveness of ALLO-501A CAR T Cell Therapy in Adults with Relapsed/ Refractory Large B Cell Lymphoma - Mayo Clinic

    The primary purpose of this study is to assess the safety and effectiveness of ALLO-501A to treat patients with relapsed/refractory large B cell lymphoma (LBCL) ...

  2. A Study of the Effectiveness and Safety of CTL019 in Adult Patients with Diffuse Large B-Cell Lymphoma - Mayo Clinic

    The purpose of this study is to determine the efficacy and safety of CTL019 in adult patients with relapsed or resistant diffuse large B-cell lymphoma.

  3. CAR-T cell therapy for lymphoma and other blood cancers at Mayo Clinic in Jacksonville, Florida

    ZUMA-7 led to the approval of axicabtagene ciloleucel for second line treatment of large B-cell lymphoma after showing better outcomes compared with ...

  4. Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma - Mayo Clinic

    Clinical Trials · Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma · More about research at Mayo ...

  5. Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-cell Lymphoma - Mayo Clinic

    Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-cell Lymphoma · Share · Facebook · Twitter.

  6. Study of Brentuximab Vedotin Combined With RCHOP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) - Mayo Clinic

    Study of Brentuximab Vedotin Combined With RCHOP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) · Overview · Participation ...

  7. A Study to Compare the Effectiveness and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas - Mayo Clinic

    ... B-cell Non-Hodgkin Lymphomas. Print details. Share; Facebook · Twitter. Overview; Participation eligibility; Participating Mayo Clinic info; More information ...

  8. Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus RCHOP in Participants with Previously Untreated High-risk Large B-cell Lymphoma - Mayo Clinic

    Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus RCHOP in Participants with Previously Untreated High-risk Large B-cell Lymphoma.

  9. A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma - Mayo Clinic

    CD20+Diffuse Large B-Cell Lymphoma. · Ann Arbor stage 3 or 4 or stage 2 with bulky disease · High or high-intermediate disease risk. · No prior anti-lymphoma ...

  10. Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) - Mayo Clinic

    Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem ...